Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy

Biomaterials

Volumn 35, Issue 25, 2014, Pages 6776-6786

  Wang, Chunming ^a,f   Poon, Selina ^a   Murali, Sadasivam ^a   Koo, Chuay Yeng ^a,g   Bell, Tracey J ^b   Hinkley, Simon F ^b   Yeong, Huiqing ^a   Bhakoo, Kishore ^c   Nurcombe, Victor ^a,d   Cool, Simon M ^a,e  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c AGENCY FOR SCIENCE   (Singapore)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f University of Macau   (Macao)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Blood vessel; Glycosaminoglycans; Heparin; Vasculogenesis; VEGF

Indexed keywords

BIOACTIVITY; CELL PROLIFERATION; CELL SIGNALING; ENDOTHELIAL CELLS; SULFUR COMPOUNDS;

ANGIOGENESIS; GLYCOSAMINOGLYCANS; HEPARIN; VASCULOGENESIS; VEGF;

BLOOD VESSELS;

HEPARAN SULFATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2; ANGIOGENIC FACTOR; PROTEIN BINDING; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BLOOD VESSEL REACTIVITY; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIS; COMPLEX FORMATION; EMBRYO; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD VESSEL; CHEMISTRY; DRUG EFFECTS; GENETIC PROCEDURES; METABOLISM; PROCEDURES; PROTEIN ENGINEERING; VASCULAR DISEASES;

ANGIOGENESIS INDUCING AGENTS; BIOSENSING TECHNIQUES; BLOOD VESSELS; CELL PROLIFERATION; HEPARITIN SULFATE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROTEIN BINDING; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84902106580     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.084     Document Type: Article

References (37)

1. Cause-specific mortality 2008, World Health Organization (WHO) Global Health Observatory Data Repository.
2. Simons M., Bonow R.O., Chronos N.A., Cohen D.J., Giordano F.J., Hammond H.K., et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation 2000, 102:E73-E86.
3. van der Laan A.M., Piek J.J., van Royen N. Targeting angiogenesis to restore the microcirculation after reperfused MI. Nat Rev Cardiol 2009, 6:515-523.
4. Annex B.H. Therapeutic angiogenesis for critical limb ischaemia. Nat Rev Cardiol 2013, 10:387-396.
5. Yla-Herttuala S., Rissanen T.T., Vajanto I., Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. JAm Coll Cardiol 2007, 49:1015-1026.
6. Beohar N., Rapp J., Pandya S., Losordo D.W. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. JAm Coll Cardiol 2010, 56:1287-1297.
7. Karvinen H., Pasanen E., Rissanen T.T., Korpisalo P., Vahakangas E., Jazwa A., et al. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther 2011, 18:1166-1172.
8. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107:1359-1365.
9. Eppler S.M., Combs D.L., Henry T.D., Lopez J.J., Ellis S.G., Yi J.H., et al. Atarget- mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002, 72:20-32.
10. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999, 13:9-22.
11. Xu D., Fuster M.M., Lawrence R., Esko J.D. Heparan sulfate regulates VEGF165- and VEGF121-mediated vascular hyperpermeability. JBiol Chem 2011, 286:737-745.
12. Cool S.M., Nurcombe V. Heparan sulfate regulation of progenitor cell fate. JCell Biochem 2006, 99:1040-1051.
13. Dombrowski C., Song S.J., Chuan P., Lim X., Susanto E., Sawyer A.A., et al. Heparan sulfate mediates the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells Dev 2009, 18:661-670.
14. Krilleke D., DeErkenez A., Schubert W., Giri I., Robinson G.S., Ng Y.S., et al. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. JBiol Chem 2007, 282:28045-28056.
15. Ashikari-Hada S., Habuchi H., Kariya Y., Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. JBiol Chem 2005, 280:31508-31515.
16. Nurcombe V., Goh F.J., Haupt L.M., Murali S., Cool S.M. Temporal and functional changes in glycosaminoglycan expression during osteogenesis. JMol Histol 2007, 38:469-481.
17. Murali S., Leong D.F., Lee J.J., Cool S.M., Nurcombe V. Comparative assessment of the effects of gender-specific heparan sulfates on mesenchymal stem cells. JBiol Chem 2011, 286:17755-17765.
18. Murali S., Rai B., Dombrowski C., Lee J.L., Lim Z.X., Bramono D.S., et al. Affinity-selected heparan sulfate for bone repair. Biomaterials 2013, 34:5594-5605.
19. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. JBiol Chem 1996, 271:7788-7795.
20. Cardin A.D., Weintraub H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989, 9:21-32.
21. Kanato Y., Kitajima K., Sato C. Direct binding of polysialic acid to a brain-derived neurotrophic factor depends on the degree of polymerization. Glycobiology 2008, 18:1044-1053.
22. Ono S., Hane M., Kitajima K., Sato C. Novel regulation of fibroblast growth factor 2 (FGF2)-mediated cell growth by polysialic acid. JBiol Chem 2012, 287:3710-3722.
23. Zhao W., McCallum S.A., Xiao Z., Zhang F., Linhardt R.J. Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Biosci Rep 2012, 32:71-81.
24. Kamakura S., Moriguchi T., Nishida E. Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. JBiol Chem 1999, 274:26563-26571.
25. Ribatti D., Nico B., Vacca A., Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 2006, 1:85-91.
26. Ashikari-Hada S., Habuchi H., Kariya Y., Itoh N., Reddi A.H., Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. JBiol Chem 2004, 279:12346-12354.
27. Huynh M.B., Morin C., Carpentier G., Garcia-Filipe S., Talhas-Perret S., Barbier-Chassefiere V., et al. Age-related changes in rat myocardium involve altered capacities of glycosaminoglycans to potentiate growth factor functions and heparan sulfate-altered sulfation. JBiol Chem 2012, 287:11363-11373.
28. Sasaki T., Larsson H., Kreuger J., Salmivirta M., Claesson-Welsh L., Lindahl U., et al. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 1999, 18:6240-6248.
29. Stringer S.E. The role of heparan sulphate proteoglycans in angiogenesis. Biochem Soc Trans 2006, 34:451-453.
30. Ferreras C., Rushton G., Cole C.L., Babur M., Telfer B.A., van Kuppevelt T.H., et al. Endothelial heparan sulfate 6-O-sulfation levels regulate angiogenic responses of endothelial cells to fibroblast growth factor 2 and vascular endothelial growth factor. JBiol Chem 2012, 287:36132-36146.
31. Grunewald F.S., Prota A.E., Giese A., Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010, 1804:567-580.
32. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001, 22:201-207.
33. Cross M.J., Dixelius J., Matsumoto T., Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003, 28:488-494.
34. Miraliakbari R., Francalancia N.A., Lust R.M., Gerardo J.A., Ng P.C., Sun Y.S., et al. Differences in myocardial and peripheral VEGF and KDR levels after acute ischemia. Ann Thorac Surg 2000, 69:1750-1753. discussion 4.
35. Lu H., Xu X., Zhang M., Cao R., Brakenhielm E., Li C., et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci U S A 2007, 104:12140-12145.
36. Webber M.J., Tongers J., Newcomb C.J., Marquardt K.T., Bauersachs J., Losordo D.W., et al. Supramolecular nanostructures that mimic VEGF as a strategy for ischemic tissue repair. Proc Natl Acad Sci U S A 2011, 108:13438-13443.
37. Carragee E.J., Hurwitz E.L., Weiner B.K. Acritical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011, 11:471-491.